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ABSTRACT 
A PILOT STUDY OF POLYCYCLIC AROMATIC HYDROCARBONS IN 
MATERNAL AND CORD BLOOD PLASMA 
March 30, 2007 
 Polycyclic aromatic hydrocarbons (PAH) are chemicals generated from 
the incomplete combustion of organic materials, including tobacco smoke.  Some 
PAH are known to be mutagenic and carcinogenic in humans, and of concern for 
the fetus when women smoke during pregnancy. Known consequences of 
smoking during pregnancy include low birth weight and preterm delivery.  It is 
unknown if PAH are related to these outcomes.  This pilot study was designed to 
measure concentrations of 3 PAH (anthracene, benzo(a)pyrene and 1-
hydroxypyrene) in paired maternal and cord blood samples as well as any 
correlations between the two matrices.  Plasma cotinine was used as a 
biomarker of tobacco exposure.  Additionally, we asked if there is any 
relationship between the PAH concentrations and low birth weight or preterm 
delivery.      
 Results showed that all 3 PAH could be found in maternal and cord 
plasma.  Anthracene was consistently shown to be significantly elevated in cord 
plasma compared to maternal plasma in subgroups based on increasing cotinine 
concentrations.  However, none of the compounds studied were correlated with 
either birth weight or gestational age.    
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INTRODUCTION 
 Environmental pollution has been around since the dawn of life on earth.  
Human-generated environmental pollution has been around at least since the 
discovery of fire in the Paleolithic Period.  The advances and discoveries of 
civilization (the Renaissance, the Industrial Revolution, fossil fuels, the 
automobile, atomic energy, etc.) have increased the rate at which human-
generated pollution has affected the health of the planet (air, water, soil) and the 
species that inhabit it. Environmental pollution is known to cause or contribute to 
a number of human diseases, including cancer, developmental disorders and 
immune, cardiovascular and pulmonary diseases. Among the many compounds 
that contribute to environmental pollution are the polycyclic aromatic 
hydrocarbons, a group of compounds with potential for carcinogenic and 
mutagenic activity in humans. 
 Polycyclic aromatic hydrocarbons (PAH) are products of incomplete 
combustion of organic matter.  They are made up of fused benzenoid rings as 
well as unsaturated 4-, 5-, and 6-membered rings.  Sources include automobile 
exhaust, coal-fired energy plants, tobacco and wood smoke, as well as 
grilled/smoked foods. (1)  PAHs are highly lipid-soluble, readily absorbed from 
the gastrointestinal tract and rapidly distributed throughout the body, especially 
into fat tissue. (2) Metabolism occurs via the cytochrome P450-mediated mixed-
function oxidase system, yielding, among other things, highly reactive epoxides 
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that are known to be carcinogenic, mutagenic and/or developmentally toxic. (3, 4) 
In studying the effects of PAH exposure, benzo[a]pyrene is widely used as a 
“representative PAH” because, at least in the urban setting, concentrations of 
individual PAHs are highly correlated.  In addition to its carcinogenic potential, 
benzo(a)pyrene has also been shown to act as an endocrine disruptor due to its 
structural similarity to the cholesterol core of many hormones and/or by 
interfering with hormonal activity (5). Among other PAH compounds, 1-
hydroxypyrene has often been followed in urine as a marker of PAH exposure.  
Anthracene, while not carcinogenic itself, has the potential for easy methylation 
at the 9- and 10- carbons on the middle ring to much more toxic compounds that 
are indeed carcinogenic (9-methyl anthracene and 10-methyl anthracene).   
 One common source of polycyclic aromatic hydrocarbons is tobacco 
smoke.  It is ubiquitous in the environment and its use is recognized as 
detrimental to human health.  It is especially problematic during pregnancy when 
the fetus is at great risk for significant harm from the chemicals that will cross the 
placenta and influence subsequent development.  This study will focus on the 
presence of 3 specific PAH among the many compounds in tobacco smoke in 
maternal and cord blood (see Figure 1). 
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Figure 1.   
Chemical structures of polycyclic aromatic hydrocarbons of interest in this 
study.  
    
Benzo(a)pyrene          1-hydroxypyrene  Anthracene  
 
BACKGROUND 
      
 Concerns about atmospheric contamination are not new.  Thirteenth 
century England was blanketed in coal smoke as Londoners switched from 
burning wood for fuel (as wood became scarce and expensive) to heating with 
sea-coal, a relatively plentiful (and cheap) but dirty alternative fuel. Such practice 
was banned by royal edict as far back as 1272, but citizens were not deterred.  
The term “smog” was coined in the early 1900s to describe the air of London, 
where naturally occurring fog combined with coal-burning smoke to envelope the 
city and surrounding areas. (6)   
 The early to mid-20th  century saw a number of air stagnation events 
(periods of extraordinarily heavy pollution) that resulted in excess deaths and 
hospitalizations among citizens in the United States and elsewhere. (7, 8)  These 
events provided well-defined intervals in which specific data (atmospheric 
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conditions, hospital admissions and deaths) could be analyzed by scientists and 
governmental officials in order to better understand the short term effects of 
ambient outdoor air quality on public health. Epidemiological studies showed 
generally that the combination of increased concentrations of smoke and sulfur 
dioxide in the air, along with a given individual’s underlying biophysiological 
susceptibility (primarily cardiovascular or pulmonary disease), resulted in 
morbidity and mortality rates up to 10-fold higher than normal. (7) 
 Environmental pollution also contributes to respiratory hypersensitization, 
which has been on the increase in Western nations over the past several years.  
Allergic diseases are the 6th leading cause of chronic illness in the U.S., affecting 
up to 17% of the population and costing $18 billion annually. (9) Particulates, 
including soot, pollen, animal dander, insects and microbes, can trigger tissue 
inflammation/injury and airway reactivity (rhinitis, asthma, chronic bronchitis, 
etc.). (10, 11) Infants and children are especially sensitive to particulate pollution. 
Despite the fact that such chronic illnesses are not generally fatal (and 
consequently not reflected in mortality data), the social impact in terms of 
hospital admissions, missed school/work days, etc. is still significant.  Studies 
from the Centers for Disease Control and Prevention have shown that up to 40 
million Americans have chronic allergic rhinitis (hay fever) related to common air-
borne allergens, resulting in approximately 3.8 million lost days of work and 
school annually (12).      
 Although overall air quality in the late 20th and early 21st centuries is much 
improved over that in the 1950s and 1960s, indoor air pollution remains a 
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significant contributing factor to morbidity and mortality.  The most ubiquitous 
indoor pollutant is tobacco smoke, which is known to contain over 4,000 
chemicals (including PAHs) and has been classified as a carcinogen by the 
United States Environmental Protection Agency.   Environmental tobacco smoke  
is made up of both mainstream smoke (that which has been inhaled by the 
smoker and then exhaled) and side-stream smoke (that emitted directly from a 
burning cigarette). Sidestream smoke is considered to be more toxic, gram for 
gram, than mainstream smoke since it contains chemicals and particulates in 
higher concentrations than smoke that has been scrubbed (filtered) by the 
smoker’s lungs. (13)  Involuntary or passive smoking (a combination of 
mainstream and side stream smoke) by individuals sharing significant amounts of 
time and space with active smokers has been shown to increase the risk of 
serious lung disease (asthma, chronic bronchitis) as well as lung cancer. (14) 
 The developing fetus is the most vulnerable of involuntary smokers.  
Studies in reproductive epidemiology have shown that fetuses and infants are 
more likely to have a heightened sensitivity to any number of environmental 
toxicants due to their degree of exposure in relation to organ mass, physiologic 
immaturity to detoxify such compounds and critical windows of growth and 
development that may be negatively impacted by such exposures.  (15-18)  
Convincing evidence already exists that relates maternal smoking during 
pregnancy with low birth weight (LBW, weight under 2.5 kg), intrauterine growth 
restriction (IUGR, weight for gestation less than 10th percentile), placenta previa 
(attachment of the placenta in the lower part of the uterus, often resulting in 
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excessive bleeding), placental abruption (precipitous detachment of the placenta 
from the uterus before birth of the infant), miscarriage and preterm delivery. (19-
41) Life-long risk for postnatal or adult-onset disease in the infant whose mother 
smoked during pregnancy has not, so far, been quantified, primarily due to 
multiple family, socioeconomic and environmental confounding factors. However, 
measurable evidence of genetic damage from environmental tobacco smoke in 
non-smokers is mounting. (42-46)  
 Using paired maternal-cord blood specimens, this study will address the 
following research questions: 
1. Are anthracene, benzo(a)pyrene and 1-hydroxypyrene present in 
measurable concentrations in maternal and cord blood plasma? 
2. Do plasma concentrations of anthracene, benzo(a)pyrene and/or 1-
hydroxypyrene correlate with cotinine among smoking and non-smoking 
women? 
3. Do plasma concentrations of  anthracene, benzo(a)pyrene and/or 1-
hydroxypyrene in cord blood parallel levels in maternal plasma? 
4. Are plasma concentrations of anthracene, benzo(a)pyrene and/or 1-
hydroxypyrene correlated with birth weight or gestational age? 
 
GENERAL ENVIRONMENTAL CONCERNS 
 Air pollution is a public health issue with political/social underpinnings.  A 
number of epidemiological studies have shown associations between 
morbidity/mortality rates and air quality all across the globe. (1, 5, 7, 11, 16, 17, 
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47-55) This research has examined risks in urban vs. rural communities, white 
collar vs. blue collar neighborhoods, indoor vs. outdoor pollution, industrialized 
vs. developing countries and across all age groups.  There is little question that 
the general health of any community is highly dependent on the quality of the air 
its citizens breathe.  However, one of the challenges of interpreting 
epidemiological studies is to quantify and control for the effects of multiple 
cofactors (social, cultural, economic).  Public policy must be a driving force for 
pollution abatement, as pollution is a product of the activities of individuals, 
industries and governments, all of which must be balanced for the good of the 
community. 
 An increasing prevalence of asthma/respiratory hypersentization has been 
noted across the globe in recent years. Bascom (10) reviewed a number of 
studies from North and South America supporting the hypothesis that 
environmental factors contribute to the development of respiratory allergy, 
asthma, and chronic bronchitis.  In addition to the usual triggers (pollen, dust 
mites, animal dander) the author discusses how ambient air pollutants (fossil fuel 
emissions, particulates, etc., both stationery and mobile) and unfavorable climatic 
conditions can compound the allergic response in individuals that have a genetic 
susceptibility to this heightened sensitivity. While “air pollution” is often used to 
imply a singular entity, it is actually variable in character depending on the 
sources, the climate, the season, and the chemicals in the mix. Human 
responses to elevations in specific pollutants can range from cough and 
shortness of breath to asthma exacerbation, lung injury and decreased lung 
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function. (56) Ozone, a secondary atmospheric pollutant formed by the 
photochemical reaction between nitrogen oxides and hydrocarbons, is often 
increased in summer months when fossil fuel emissions react with sunlight.  
Exercising in an elevated ozone environment can lead to decreased lung 
function, tissue injury and inflammation, all of which are measurable for hours 
after exposure ceases.  Epidemiologic studies show that such conditions are 
associated with increased hospitalizations and emergency department visits for 
individuals with respiratory risk factors. (56) 
 Particulate matter (PM) has been shown increasingly in recent years to be 
an important factor in defining air quality, due to effects on heart and lung health. 
PM is a complex mixture of small particles and liquid droplets, with particle size 
directly linked to potential for negative health effects.  (57)  Particulates that are 
10 micrometers (microns, µ) or smaller are of the strongest concern because 
they are generally not filtered out by the upper airway (nose and throat), and 
pass on into the lungs.  Coarse particles, 2.5 – 10 µ in diameter) are often 
detected in dusty areas/regions and near industrial sites.  Fine particles, 2.5 µ or 
smaller) are common components of smoke and haze and found in the 
emissions of power plants, industries and auto exhaust.  
 Dockery et al conducted a prospective, cohort study of air pollution and 
mortality among adults in 6 United States cities from 1974-1991. (48)  At the time 
of enrollment, subjects underwent baseline spirometric testing and completed 
questionnaires detailing medical and smoking history, as well as occupational 
exposures.  During the intervening years, subjects were contacted annually for 
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updates on medical and vital status.  Ambient air quality data were obtained from 
governmental sources. Death certificates were obtained for 98% of those who 
died during the study period; causes of death were independently verified. After 
adjusting for smoking behavior and other risk factors, there remained a 
statistically significant association between air pollution (especially fine 
particulates) and mortality (adjusted rate ratio 1.26 (95% C.I. 1.08-1.47).  
Epidemiological studies from South Korea, (51) Czechoslovakia (47) Mexico (53) 
and California (58) have shown that even among infants, after controlling for 
premature birth and underlying respiratory disease (e.g. bronchopulmonary 
dysplasia), there is credible evidence that fine particulate matter (PM2.5 ) air 
pollution contributes to respiratory-related deaths in the post-neonatal period.   
 In the Louisville, KY region of the Ohio Valley, air pollution control is a 
constant battle, especially in the summer months when heat, humidity and 
stagnant weather patterns exacerbate baseline pollution conditions. While air 
quality is much improved over the mid- late- 20th century, the region still saw 8 
days of excessive ozone (U.S. Environmental Protection Agency standard > 85 
parts per billion for 8 hours), in the year 2005. (59)  In terms of PM2.5, a more 
recently implemented pollution control measure, the Louisville Metro area 
continues to struggle with significant elevations, primarily in the summer months.  
In each year from 1999-2005, concentrations of  PM2.5 exceeded the acceptable 
standard (15 µg/meter3) in the months of June, July and August from 1.1-2.0 fold. 
(60)  Reports from the first 5 months of 2006 showed that PM2.5 pollution was 
significantly down from previous years and met/exceeded the national standard.  
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Data from the summer months of 2006 were not available at the time of this 
paper.  
 Environmental pollutants can also impact the orderly development of 
organisms as well as normal cellular processes. Pesticides, (61-63)  radiation, 
(64, 65) and heavy metal compounds (17, 66-68), whether in the water, soil or 
air, all have the potential to cause disruptions in the normal maturational 
sequence. During embryogenesis and even beyond, the presence (or absence) 
of chemical signals can permanently alter the structure and function of cells, 
tissues and organs.  Slotkin et al have shown the disruptive effect of nicotine, a 
neurologically active chemical with specific receptors, on the developing brain in 
a rat model. (69) When a pregnant rat was exposed to an infusion of nicotine 
comparable to that found in (human) heavy smokers, there were 4 major 
neurological effects in the post-natal rat pup, including presence of markers of 
cell damage, decreased numbers of cells, inhibition of DNA synthesis and 
blunted synaptic activity in the forebrain. These effects indicate that, at least in 
the rat, nicotine, one of many chemicals humans acquire primarily through 
cigarette smoking, is a nervous system teratogen associated with significant 
short and long-term alterations in normal brain development.    
 In the human brain, nicotine reacts with nicotinic acetylcholine receptors, 
(70) which appear as early as 4-5 weeks’ gestation.  As in the rat model, these 
receptors are involved in modulating dendritic outgrowth, establishment of 
neuronal connections and synaptogenesis during development.  (71) In the 
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immature brain, stimulation of these receptors leads to interaction with the genes 
that control cell replication, differentiation, growth and death. (72)  
 Epidemiological studies have suggested that in-utero exposure to nicotine 
is associated with negative neurobehavioral effects later in childhood and 
adolescence. (73-76)  However, the confounding effect of socioeconomic factors 
on childhood behavior have made direct linkage between smoking and later 
behavior difficult to interpret.  Recently, Maughan et al, using the Longitudinal 
Twin Study of Britain, showed that prenatal smoking had a strong and statistically 
significant dose-response relationship to childhood conduct disorders at 5 and 7 
years of age, especially in boys. (77) The researchers found that approximately 
two-thirds of the variation in the reported conduct problems at each age was 
found to be attributable to genetic factors.  However, after controlling for the 
genetic influences, prenatal smoking in the mother continued to predict such 
problems.  In an effort to account for more potentially confounding factors, the 
researchers measured social-environmental factors that may have contributed to 
the observed behaviors.  Once parental antisocial behavior, maternal depression 
and social deprivation were controlled in the analysis, in addition to the genetic 
risk, the strong initial effect of smoking on early childhood conduct was reduced 
by about 75%.  For children of women that were light-moderate smokers, the 
effect was non-significant. For children of women that were heavy smokers, the 
effects could still be detected, but the magnitude was greatly reduced.      
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SMOKING EFFECTS AND CONCERNS  
 Among adults in the U.S., tobacco smoke has been officially linked to 
cancer and cardiovascular disease in active smokers since the first Surgeon 
General’s Report on Smoking and Health in 1964. (78)  This report summarized 
the results of more than 7,000 published articles that correlated smoking with 
specific diseases.  Since 1964, there have been 28 additional supplements and 
reports from the Office of the Surgeon General that further describe the health 
risks from exposure to environmental tobacco smoke.  Other scientists from the 
fields of medicine and public and environmental health continue to report on the 
dangers of environmental tobacco smoke to users and those who share common 
breathing space.  Recently (June 2006), the current Surgeon General, Richard H. 
Carmona, issued a comprehensive scientific report that concludes “there is no 
risk-free level of exposure to secondhand smoke.” (14)   
  As noted in Table 1, adapted from “Cigarette Secrets,”(79) tobacco smoke 
contains a broad array of chemicals from multiple classes that are present in both 
mainstream and side stream smoke.  All of those listed are considered by the 
International Agency for Research on Cancer (IARC, a part of the World Health 
Organization) to have sufficient scientific evidence of  carcinogenicity or 
tumorigenesis  in animals.  Those with “sufficient” evidence of carcinogenicity in 
humans are noted with an S.  Those with “limited” evidence are noted with an L.  
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Table 1.   
A partial list of toxic and carcinogenic compounds in tobacco and tobacco 
smoke. (79) 
 
Polycyclic Aromatic Hydrocarbons Aldehydes
Benz[a]anthracene Formaldehyde 
Benzo[b]fluoranthene Acetaldehyde 
Benzo(a)pyreneS Miscellaneous inorganics:
Chrysene ArsenicS
Di-benzo(a,h)anthracene CadmiumL
N-Nitrosamines ChromiumS
N-Nitrosodimethylamine Lead 
N-nitrosoethylmethylamine NickelL
N-nitrosonornicotine Polonium 210S
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Tobacco smoke is one of the most ubiquitous indoor air pollutants.  In 
addition to the chemicals and carcinogens known to be contained in tobacco 
smoke, it also contains significant amounts of particulates, including small, 
respirable ones (PM2.5). (80, 81)  By virtue of the differences in respiratory rate 
and minute ventilation between infants and adults, infants and toddlers inhale a 
larger dose of air pollutants per unit of body mass than adults breathing the same 
air; they also appear to be more vulnerable to the effects.  Using data from the 
Third National Health and Nutrition Examination Survey (1988-1994), Gergen et 
al (58) reported that respiratory complications from exposure to environmental 
tobacco smoke (asthma, chronic bronchitis, and wheezing) were more common 
in children 2-20 months than in children 3-5 years of age.  After adjusting for 
relevant confounding factors, the authors determined that the excess attributable 
risk for these respiratory complications showed that 40-60% of the cases could 
be linked to environmental tobacco exposure.      
 A causal association between involuntary smoking (passive tobacco 
smoke exposure) and lung cancer appears to exist, as the risk among non-
smoking spouses has been shown to be increased 20-30% over non-smokers in 
general. (13, 82, 83) In the United States, a meta-analysis of 11 epidemiological 
studies showed that environmental tobacco smoke may be responsible for as 
many as 3,000 lung cancers annually in non-smokers (35 and over) and up to 
35,000 deaths. (13)  Studies have shown that adults exposed passively to 
tobacco smoke in the workplace often develop respiratory symptoms such as 
wheezing, cough, etc.  However, it is unclear if, or to what extent, this exposure 
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explains chronic obstructive pulmonary disease or cardiovascular disease in non-
smokers.   
 In Kentucky, where tobacco has been a prominent cash crop throughout 
the Commonwealth’s history, over 8,000 citizens die of tobacco-related diseases 
each year.  In 2005, Medicare and Medicaid costs related to the health effects of 
tobacco were estimated to be $1.2 billion, or $300/Kentuckian. (84)  Kentucky 
exceeds the national average in prevalence of tobacco use in all age categories 
(adult, high school and middle school), racial/ethnic groups (whites, African-
Americans), gender and during pregnancy. By far, annual deaths from cancers of 
the trachea, lung and bronchus are the leading causes of smoking-attributable 
mortality (SAM). 
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Table 2.   
Comparisons of tobacco use  and consequences in Kentucky and in the 
U.S. (84, 85) 
 
 Kentucky U.S. 
Any tobacco (%) 28 21 
Males (%) 29 23 
Females (%) 26 19 
Caucasians (%) 29 22 
African-Americans (%) 30 20 
Hispanics (%) 16 15 
Middle school (%) 24 13 
High school (%) 44 28 
During pregnancy (%) 24 11 
Years of potential life lost (per 100,000 persons) 5,597 3,805 
Smoking Attributable Mortality (per 100,000 persons) 385 273 
 
SMOKING CONCERNS AMONG MOTHERS AND INFANTS 
 For infants and children, it has been shown that living in homes with 
tobacco smoke clearly results in more coughing, wheezing and respiratory illness 
than living in smoke-free homes. (13, 58) In the United States, it is estimated that 
35-40% of children live in homes where others smoke. (86) Diagnoses of 
asthma, chronic bronchitis and wheezing increase with increasing environmental 
tobacco smoke exposure and with decreasing postnatal age. (58)     
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 Among women of childbearing age, the negative effects of environmental 
tobacco smoke can reach beyond personal health risks to those of a developing 
fetus.  Multiple studies have addressed the consequences of maternal smoking 
during pregnancy both for the mother and the infant: increased risk for premature 
rupture of membranes, (87, 88) premature birth and low birth weight (birth weight 
<2.5 kg), (89-91) placenta previa/abruption, (92) miscarriage, and stillbirth. (93, 
94)  
 The link between smoking during pregnancy and LBW was first reported 
by Simpson in 1957 (35) and has been confirmed in numerous reports since.  
This effect is independent of other factors that influence birth weight, including 
gestational age, gender, parity, race, pre-pregnancy anthropometrics, and 
socioeconomic status.  A series of 14 studies from the United States, Canada, 
the United Kingdom, Italy, Norway and Sweden during the years 1959-91 were 
compared in the 2001 Surgeon General’s Report on Women and Smoking. (36) 
Smoking intensity was defined by either maternal report or cotinine 
concentrations. Infants of smokers were 66-320 grams lighter at birth when 
compared to infants of non-smokers.  In general, the more a woman smoked, the 
larger the birth weight deficit when compared to the infant of a non-smoker.   
 The primary mechanism of reduced fetal growth due to smoking is 
presumed to be a combination of relative hypoxia due to placental 
vasoconstriction and carbon monoxide binding to fetal hemoglobin oxygen.(95-
97) However, it is possible that other mechanisms, including altered nutrient 
metabolism, contribute as well. (98-101)  Studies by D’Souza et al (26) and 
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Harrison et al (102) showed that the reduction in birth weight was related to loss 
of lean mass rather than reduced fat deposition, which is consistent with an 
hypoxic or other non-nutritional mechanism.  Smoking during the first trimester of 
pregnancy is temporal with cellular hyperplasia and organogenesis.  Any of these 
mechanisms may function to alter or restrict the normal developmental pattern or 
influence a critical window that cannot be recovered. 
 Smoking cessation during pregnancy can lead to gains in birth weight and 
reductions in the likelihood of low birth weight.  Secker-Walker et al conducted 
clinical trials examining smoking cessation and relapse prevention. (103) They 
ascertained cigarette consumption by both maternal report and urinary cotinine 
levels and found that women who stopped smoking early in pregnancy (before 
the first prenatal visit) and remained abstinent could reduce the expected birth 
weight loss by as much as 300 grams.  
 England and colleagues compared the effects of 3 different patterns of 
cigarette exposure during pregnancy (quit, reduced, increased) with women 
whose smoking behavior did not change. (104) Patterns were determined by  
personal report and urinary cotinine measurements.  Women that reduced/quit 
smoking before or soon after study enrollment delivered infants that were, on 
average, ~32 grams heavier than babies of women that continued the same level 
of smoking.  However, when birth weight was stratified by maternal cigarette use 
at enrollment, infants of women with low exposure who then reduced their 
cigarette consumption were ~200 grams heavier than infants of women who were 
light, but consistent, smokers. 
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 In Kentucky, the incidence of low birth weight has been higher than the 
national average for the past decade.  This is accompanied by a high prevalence 
of smoking during pregnancy, with rates in Kentucky usually the highest in the 
nation. 
Table 3.   
Prevalence of low birth weight (% live births) and smoking during 
pregnancy in the United States and Kentucky in 3 time periods.  (105) 
 
1995-1997 1998-2000 2001-2003  
 
%  LBW 
% 
Smokers 
 
% LBW 
% 
Smokers 
 
% LBW 
% 
Smokers
Kentucky 7.8 24.5 8.2 24.5 8.6 24.4 
U.S.  7.4 13.6 7.6 12.6 7.8 11.4 
 
 Specific studies have addressed the effects of smoking on indices of 
newborn health.  Symptoms of neonatal nicotine withdrawal, including jitteriness 
and irritability, have been described by multiple authors. (106-109)  Alterations in 
body composition and growth have been known and studied for decades. (23, 
92, 110-113) Evidence suggests that there is a dose-response as well as a 
temporal relationship between smoking and reduced birth weight. (22, 28, 104, 
114-116)  The earlier in her pregnancy a woman quits, the smaller the effect on 
her infant’s birth weight. (104, 117) Smoking also is associated with lower levels 
of markers of bone metabolism in infants of smoking mothers when compared to 
those of women that do not smoke. (118-121) The biological explanations for 
these effects have centered on immunologic (100) as well as physiologic 
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pathways. (122)  Postnatally, an increased risk for Sudden Infant Death 
Syndrome (SIDS), (123, 124) upper respiratory tract infection, and asthma has 
been linked to smoking by adults in the child’s environment (58, 125, 126).   
 According to the Centers for Disease Control and Prevention (CDC), the 
prevalence of smoking during pregnancy in the United States in 2002 was 
estimated to be 11.4%, a decrease of 38% from 1990. (127)  During that same 
12-year period, the rate in Kentucky decreased only 14.4% to 24.4%, a rate 
exceeded only by pregnant women in West Virginia (26.2%). Among females 
aged 15-19, the rate of smoking during pregnancy in Kentucky increased from 
32.9% to 34.1% (1990-2002).  Only Vermont, New Hampshire and West Virginia 
had teen rates that were higher during that period.  Figure 2 shows that the 24% 
overall rate for Kentucky, while alarming in an of itself, does not convey that there 
are regions of extremely high tobacco use in certain parts of the Commonwealth 
where the prevalence is 3-4 times that across the United States.  Coupled with 
the increased rates of prematurity and low birth weight, the financial burden on 
Kentuckians related to smoking during pregnancy is significant.  CDC analysis of 
data from pregnancy risk surveillance and birth certificates resulted in an 
estimate of smoking-attributable neonatal expenditures (in 1996 US dollars) of 
$704 per maternal smoker (range $519-1,334) both nationally and in Kentucky. 
(128)  
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Figure 2.   
Prevalence of smoking during pregnancy in Kentucky by county.  (84) 
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The impact of personal cigarette smoking in the short term (pregnancy 
and the neonatal period) on the health of mothers and infants has been 
discussed.  However, passive exposure to tobacco smoke at home or in the work 
place can also be detrimental to a woman and her infant during pregnancy and 
postnatally.  Side stream smoke represents approximately 85% of total 
environmental tobacco smoke and contains higher concentrations of some 
carcinogens than does mainstream smoke. (13) Outcome studies comparing 
birth weight of infants of pregnant non-smokers passively exposed to tobacco 
smoke to infants of non-exposed women have had varied results.  Generally, 
though, they show that the birth weight reduction in infants of passively exposed 
women was smaller than that seen in infants of active smokers. (38, 129) Horne 
et al. and others have reported that infants exposed pre- and post-natally to 
tobacco smoke have decreased arousability from sleep, (130-133) which may be 
a contributing factor to sudden infant death syndrome (SIDS).  Although the 
specific cause of SIDS remains elusive, since the introduction of the “Back to 
Sleep” program in the early 1990’s, deaths from SIDS have declined by almost 
50%, leaving exposure to environmental tobacco smoke as one of the strongest 
remaining (and modifiable) risk factors for this event. (134) Infants and children 
chronically exposed to tobacco smoke in the home also have a significantly 
increased risk of developing asthma, allergies and upper respiratory infections 
(bronchitis, ear infections, pneumonia). (58, 135-137).   
 Tobacco smoke is a toxicant to the embryonic, fetal and postnatal lung 
and can exert varying degrees of harm throughout gestation and beyond, based 
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on the stage of lung development (proliferation, differentiation, branching) at the 
time of the exposure. (17) Enzyme systems necessary for intrapulmonary 
metabolism as well as the detoxification of foreign molecules (epoxide hydrolase, 
cytochrome P450 mono-oxygenases, glutathione-S-transferase, and other anti-
oxidant systems) mature at differing rates throughout gestation and after birth.  
Exposure to damaging compounds prior to the availability of these enzymes may 
permanently alter their developmental profile.  Molecular signals orchestrate the 
process temporally and spatially throughout the continuum from embryogenesis 
through adolescence, when lung growth is generally complete. Substances that 
interfere with these signals may result in deviant lung development.  Although a 
normal term pregnancy (40±2 weeks) allows for development that is adequate to 
sustain life, fully 80% of lung development occurs after birth. (17) Continued 
exposure to pollutants such as tobacco smoke perpetuates the risk for altered 
development.   
 Nicotine (a component of the tobacco leaf and tobacco smoke) is readily 
transported to the fetal compartment via the placenta. (15) Luck et al. showed 
that the serum nicotine ratio (umbilical vein/maternal) was 1.12±0.3, evidence 
that it is concentrated in the fetus compared to the mother. (138) The authors 
also found that nicotine in the amniotic fluid was increased up to 88% relative to 
maternal serum values.  Nicotine’s effects include decreased uterine artery blood 
flow, variable changes in umbilical artery flow, changes in fetal oxygenation (due 
to the binding of carbon monoxide to fetal hemoglobin) and acid base balance, 
as well as decreased fetal heart rate and increased mean arterial pressure. 
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(139).  Nicotine has been shown to be toxic in adults with doses as small as 2 
mg. (140) 
 Amniotic fluid,  which bathes, nourishes and cushions the fetus during 
gestation, actually  represents fetal urine.  During the first trimester of pregnancy, 
it is derived from maternal blood plasma that diffuses through the tissues of the 
fetus into the surrounding fluid.  From approximately 10-11 weeks (simultaneous 
with the formation of fetal kidneys), the major component of amniotic fluid is fetal 
urine, supplemented with growth factors and secretions from the lungs, oral and 
nasal cavities, as well as the fetal surface of the placenta.  This fluid is constantly 
circulated as the baby "inhales" (swallows) existing fluid and replaces it through 
"exhalation" (urination). The fetal skin is highly permeable prior to keratinization 
(about mid-gestation) and readily absorbs compounds present in the surrounding 
fluid. Thus, from around 10 weeks of gestation, the fetus of a smoking mother is 
chronically exposed to tobacco products by multiple routes:  maternal circulation, 
placental transport, dermal and gastrointestinal absorption. (141, 142) 
 Cotinine is the major metabolite of nicotine and it has been used for a 
number of years as a biomarker of exposure to cigarette smoke due to its 
chemical stability, persistence in the blood stream (half-life ~24 hours) and 
freedom from interfering substances.  Jauniaux et al detected cotinine in fetal 
fluids as early as 7 weeks’ gestation. (141)  Donnenfeld et al measured 
simultaneous serum cotinine concentrations in a small number of maternal/fetal 
pairs undergoing clinically-indicated percutaneous umbilical blood sampling 
between 21 and 36 weeks gestation, (143) finding a mean fetal/maternal cotinine 
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ratio of 0.9 (95% CI 0.83-0.97).  Eliopoulos et al measured nicotine and cotinine 
in hair of newborn infants, finding a dose response based on maternal smoking 
behavior and a linear relationship between cotinine levels in individual mothers 
and babies. (144) It is not clear if the cotinine measured in fetal tissues/fluids is 
the product of fetal metabolism of maternal nicotine or if it is maternal cotinine 
passed to the fetus via the placenta. (143) 
 In pregnancy, the placenta is the organ of exchange between the fetal and 
maternal circulations.  It is made of fetal (chorionic) and maternal (endometrial) 
components and serves to provide nutrition, respiration and excretion for the 
fetus. These functions are carried out through metabolic, transfer, endocrine and 
immunologic activities.   Compounds that enter the mother’s body (nutrients, 
medications, toxins, etc.) may travel directly to the fetus or may be modulated by 
maternal metabolism or placental activity.  While the human placenta can 
metabolize many foreign chemical compounds, the breadth of metabolizing 
enzymes is more limited than in the liver which is the primary detoxifying organ.  
Hakkola et al showed that there may be a gestational influence on the 
appearance and duration of effect of some of the cytochrome-P (CYP) family 
enzymes. (145, 146) Their studies revealed that mRNA for several CYP enzymes 
was present in human placental tissue as early as the first trimester, when mitotic 
frequency is high and there is rapid functional and structural development.  They 
also showed that the number of different mRNAs that were detectable decreased 
as the pregnancy reached term.  The presence of toxic substances, such as 
PAH, in placental tissues or fluids during critical windows of development is 
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alarming in view of the high rates of hyperplasia and hypertrophy in the placenta 
and the fetus and the potential for disruption of normal maturational processes. 
 PAH are known to cross the placenta, although animal experiments have 
indicated that the fetal dose is probably an order of magnitude less than that 
presented to maternal organs and tissues.  (147-149) Yet, further animal studies 
have shown PAH administration/exposure in the pregnant female can lead to 
tumor development in the offspring in a multitude of organ systems, including 
liver, lung, lymphatics and central nervous system (150-152). 
 The presence of PAH compounds in placental tissues from both smoking 
and non-smoking women has been demonstrated by Gladen et al (153).  
Placentae were drawn from births in two Ukrainian cities participating in the 
European Longitudinal Study of Pregnancy and Childhood (ELSPAC) a program 
of the World Health Organization.  The Ukraine ELSPAC study was conducted by 
the Ukrainian Institute of Pediatrics, Obstetrics and Gynecology in cooperation 
with the University of Illinois School of Public Health.  The cities were known to 
have a history of significant industrial air pollution problems. Smoking status of 
the mothers was determined by questionnaire at 20 weeks gestation. Seven 
specific PAH were measured (including anthracene and benzo(a)pyrene).  Levels 
were generally higher in smokers when compared to non-smokers.  However, of 
178 samples analyzed, only 8 (4.5%) were from women that admitted to being 
current smokers; 21% classified themselves as ex-smokers.   
 Madhavan et al (154) reported the presence of benzo(a)pyrene, 
dibenzo(a, c)anthracene and chrysene in maternal blood, cord blood, breast milk 
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and placental tissue from non-smoking Indian women.  Except for 
benzo(a)pyrene, the other PAH compounds were higher in concentration in cord 
blood than other matrices; benzo(a)pyrene was highest in maternal milk.  The 
authors believed the primary source to be grilled/fried foods common in the diet 
in that population.  The lipophilic nature of PAH helps to explain the elevated 
concentrations in human milk but also reveals human milk to be a significant 
source of exposure for the breast-feeding infant. 
 
PROGRAMMING IN-UTERO AND CHRONIC DISEASE IN ADULTS 
 By definition, an embryo, later a fetus, is expected to spend approximately 
280 days in a developmental continuum:  hyperplasia and hypertrophy, cellular 
replication and organ maturation.  Periods of extreme cellular activity may 
justifiably be called critical windows in which the absence of an essential factor or 
the presence of a noxious substance may result in altered development.  Strong 
evidence exists that environmental exposures of various kinds during pregnancy 
can have profound effects that may predispose an infant to vulnerabilities in the 
postnatal period and beyond, (155) a concept that has been termed 
“programming” by some researchers.  
 The theory of “programming” is based on the hypothesis that in-utero or 
early childhood events/exposures that occur at sensitive or critical periods of 
development may alter the structure, physiology and/or metabolism of an 
individual for a lifetime. (156)  Barker and others have written extensively about 
the evidence for this theory and have shown that the risk for a number of adult, 
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chronic diseases can be associated with sub-normal size at birth (low birth 
weight). (156-159) The list of candidate diseases includes coronary artery 
disease (CAD), (160-162) insulin resistance/type II diabetes, (163-165) 
hypertension, (22, 166, 167) and obesity. (168)  The exact mechanism for 
expression of in-utero events decades after they occurred is not known, but 
speculation has centered on altered programming of the hypothalamic-pituitary 
adrenal axis (169, 170) which may manifest as alterations in secretion of cortisol 
(171, 172) and/or insulin-like growth factor. (173) Whether the alteration in 
cortisol is an increase (171, 172) or a decrease (174-176) is unclear.  What is 
intriguing is that thinness at birth, coupled with an increased “tempo of growth” in 
childhood appears to translate into an increased risk for heart disease in later 
adulthood. (161) The classic outcome in infants of mothers that smoke is lower 
birth weight than in infants of women that do not smoke.  Is there any reason to 
believe that the high prevalence of such adult morbidities as coronary artery 
disease, diabetes and obesity in Kentucky can be linked, at least to some 
degree, with the historic pattern of maternal smoking during pregnancy? 
 This pilot study was designed to investigate the presence of 3 specific 
PAH, all with carcinogenic/mutagenic potential, in maternal-cord blood 
specimens from women living in the Jefferson County Kentucky region. An 
additional objective was to determine if there was any relationship between those 
PAH and birth weight or gestational age.  
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MATERIALS AND METHODS 
 This study was approved by the University of Louisville Institutional 
Review Board and the Norton Hospital Research Office prior to initiation.   
 Blood samples were collected at Norton Hospital, an urban delivery center 
in Louisville, KY. The maternal population has been shown in past studies to be 
comprised of 30-40% smokers (from light to heavy) as well as multiple 
ethnicities. Anonymous paired specimens (maternal and cord) were drawn by the 
labor and delivery staff into tubes containing the anti-coagulant lithium heparin. 
Maternal specimens were drawn with other ordered labs at the time of admission.  
Cord blood specimens were drawn at the time of delivery.  Tubes were identified 
only by an ID code, M (maternal) or C (cord), with birth weight (BW) and 
estimated gestational age (GA) provided on the label.  Tubes were refrigerated at 
4-8°C in the hospital blood bank and retrieved within 24-72 hours of collection. 
 Tubes were centrifuged for 15 minutes at 3500 rpm to separate plasma 
from packed cells.  Plasma was aliquoted into low temperature freezer tubes, 
labeled with the code number and then stored frozen ( -75°C) in the Neonatal 
Research Laboratory until analyzed. Packed red cells were stored separately in 
the original tube for other analyses.  Plasma was thawed at room temperature 
and sonicated for 5 minutes prior to analysis. 
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BIOCHEMICAL ANALYSIS  
Reference standards were obtained from Dr. Steven R. Myers in the 
Department of Pharmacology and Toxicology at the University of Louisville 
School of Medicine. Stock solutions of anthracene, 3,4,8,9,-dibenzo(a)pyrene 
and 1-hydroxypyrene were prepared in HPLC-grade dichloromethane (Burdick 
Jackson)                .   
Chromatography was performed with a Waters High Pressure Liquid 
Chromatography system (HPLC) consisting of an M600E delivery system, M717 
autosampler, M996 photodiode array detector (PDA) all of which were controlled 
by Waters Empower Build 1154 software (version 5.00.00.00) running on a Dell 
Dimension 8100 computer with Windows XP Professional operating system. The 
analytical column was a 25 cm x 10 mm C18 (Waters) packed with Ultrasphere 
ODS (5µ pore size). The carrier solvent was 100% acetonitrile (Burdick Jackson 
HPLC grade) running isocratically at 1 mL/minute.  The injection volume was 10 
µL. PDA detection was full spectrum (190-600 nm) with resolution of 1.2 nm.  
Each standard was run in multiple dilutions to establish linear reference curves 
for each compound.  See figures 3-5. 
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Figure 3.    
Standard curve of anthracene.  Waters HPLC System with Photodiode 
Array detection 190-600 nm. 
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Figure 4.   
Standard curve of benzo(a)pyrene.  Waters HPLC System with Photodiode 
Array detection 190-600 nm. 
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Figure 5. 
Standard curve of 1-hydroxypyrene. Waters HPLC System with photodiode 
array detection 190-600 nm. 
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Chromatograms for each compound were extracted at 254 nm prior to 
integration which was performed with the same Waters software, using individual 
PAH standard curves as references (see figure 6). 
Figure 6.   
 
Chromatogram of anthracene, 1-hydroxypyrene and benzo(a)pyrene.  
Waters HPLC System with photodiode array detection, extracted at 254 nm. 
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 Plasma (~500 µl) was pipetted into 13x100 mm borosilicate tubes.  One 
mL of HPLC-grade ethyl acetate was added, tubes were agitated vigorously on a 
Vortex Jr. platform for 1 minute and then centrifuged for 15 minutes at 3500 rpm.  
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If a plasma volume less than 500 µl of plasma was available for analysis, the 
sample was still extracted with 1 mL of ethyl acetate,  noting the plasma volume 
used. The supernatant was transferred to a clean tube and the extraction 
process repeated.  The supernatants were combined and dried under nitrogen in 
a chemical hood at room temperature.  When the solvent had evaporated, tubes 
were capped and refrigerated at 4°C until analyzed.  The residue was warmed to 
room temperature and then reconstituted with a volume of dichloromethane  
(Fisher Scientific) equal to the original plasma volume.  Tubes were sonicated for 
1 minute and the reconstituted extract transferred to numbered sample vials 
before placing on the autosampler for analysis.    
 
COTININE  
 Enzyme Linked Immunoassay (ELISA) kits for cotinine determination were 
obtained from Cozart Bioscience, Ltd.  (Oxfordshire, UK).  Kits included 96-well 
plate, standards, wash buffer, enzyme, substrate, and stop solution.     
 Twenty microliters (µL) of standards (0 to 50 ng/mL) or unknowns (in 
duplicate) were added to individual wells coated with anti-cotinine antibody.  
Cotinine enzyme conjugate (100 µL) was added to each well and the plate 
incubated at room temperature for 30 minutes.  Wells were then washed three 
times with 350 µL of wash buffer to remove any non-specific plasma 
components.  One hundred µL of 3,3’,5,5’ tetra methyl benzidine (color reagent) 
were added to each well and the samples incubated again at room temperature 
for 30 minutes.  One hundred µL 3 N HCl were added as a stop solution.  Final 
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absorbance was measured at 450 nm on a Biotek ELX-800 microplate reader 
controlled via Dell Dimension 8100 computer with Windows XP Professional and 
Biotek KC4 software.  Concentrations of the unknowns were calculated against 
the standard curve. 
 
STATISTICAL PLAN AND ANALYSIS 
POWER AND SAMPLE SIZE CONSIDERATIONS 
 There were no preliminary data or published studies available from which 
we could extract reliable estimates of the anticipated effect sizes in this study.  
Since the primary focus of the statistical analysis for this study will be a 
comparison of the PAH and cotinine levels in the matched maternal serum-cord 
blood samples, we based our sample size calculation on the value of n required 
to achieve 80% power for detecting a small to medium effect size when using the 
paired t-test to compare the mean PAH and cotinine levels between the matched 
maternal serum and cord blood samples.  Using a two-tailed paired t-test with a 
significance level of 0.05, a sample size of 60 matched samples would yield 80% 
power for detecting a true effect size of 0.35. (177)  [Under Cohen’s  
classification scheme for effect sizes, 0.2 is considered small and 0.5 is 
considered medium.]  This sample size of 60 will also yield 80% power for 
detecting a true correlation as small as 0.35 between any two analytes (e.g., 
maternal cotinine vs. cord anthracene) using a significance level of 0.05.  A 
correlation of this magnitude is considered to represent a medium effect size 
according to Cohen’s scheme.  A total sample size of 60 (corresponding to 30 in 
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each of two independent groups) will yield 80% power for detecting a large 
sample size (0.80 in Cohen’s scheme) when using the independent samples t-
test with a significance level of 0.05.  However, independent group comparisons 
will not be a major focus of the analyses in this study. 
 All statistical analyses were conducted with SPSS v.14. Graphs were 
produced with Sigma Plot 10.0.  Comparison of maternal and matched cord 
plasma samples was conducted with paired T-tests.  Sub-group comparisons 
were conducted with the independent t-test.  Logarithmic transformations were 
applied prior to examining associations between maternal serum and cord blood 
concentrations to improve interpretability of scatterplots.  Spearman correlations 
were used to measure associations between maternal and cord blood 
concentrations.  Statistical significance was set at p<0.05.
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RESULTS 
 Eighty-nine paired specimens were acquired from labor and delivery for this 
cross-sectional study.  Of those, 25 had incomplete data, lacking either birth 
weight, gestational age or both.  Sixty-four specimens were considered complete 
and included in the study.  Infants with birth weight <2.5 kg were considered low 
birth weight (LBW).  The proportions of LBW infants (12.5%) in this study sample 
exceeded the expected Kentucky rate (~8%) by 60%.  Infants born before 38 
completed weeks’ gestation were considered to be preterm (PT);  those 
completing 38 or more weeks were considered term (T).  The proportion of PT 
infants (27.7%) in this sample exceeded the expected rate (~12%) by over 200%.  
No infants were considered to be post-term (>42 weeks).  Among term infants, 
one was large for gestational age (>90th percentile) and 2 were small for 
gestational age (<10th percentile). None of the preterm infants demonstrated 
aberrant fetal growth.  Table 4 describes the specimen pool. 
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Table 4. 
Demographics of maternal-infant pairs. (Mean, 95% C.I.) 
 All Term Preterm 
N 64 (100%) 46 (72%) 18 (28%) 
Birth Weight  
(kg) 
3.08  
(2.92, 3.23) 
3.22  
(3.09, 3.34) 
2.07 
(1.67, 2.47) 
Gestational  
Age (weeks) 
38.1  
(37.6, 38.6) 
38.5  
(38.1, 38.8) 
35.6  
(32.5, 38.6) 
Low Birth  
Weight (<2.5 kg) 
8 (12.5%) 3 (6.5%) 5 (27.7%) 
 
 The mean cotinine concentration in maternal plasma (47.5 ± 17.2 ng/mL) 
was strongly suggestive of high proportions of smoking women among this 
cohort.  There were no statistically significant differences in concentrations of 
anthracene, 1-hydroxypyrene or benzo(a)pyrene between maternal and cord 
plasma (Table 5). 
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Table 5. 
Concentrations of anthracene, benzo(a)pyrene, 1-hydroxypyrene and 
cotinine in maternal and cord blood plasma. (Mean, 95% C.I.) 
 
 Maternal Plasma 
N=64 
Cord Blood Plasma 
N=64 
 
p 
Anthracene 
(pmol/mL) 
7.0  
(4.2, 9.8) 
8.7  
(5.6, 11.9) 
0.338 
Benzo(a)pyrene 
(pmol/mL) 
4.9  
(3.3, 6.6) 
3.6  
(2.8, 4.4) 
0.174 
1-Hydroxypyrene 
(pmol/mL) 
274.2 
(233.4, 315.1) 
279.0 
(242.0, 315.9) 
0.864 
Cotinine  
(ng/mL) 
47.5  
(43.2, 51.8) 
46.2  
(39.5, 52.8) 
0.732 
 
 When groups were distinguished by low birth weight (LBW) or not, there 
were no significant differences for either maternal or cord plasma concentrations 
(See Table 6).   
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Table 6.   
Concentrations of anthracene,* benzo(a)pyrene,** 1-hydroxypyrene# and 
cotinine by low birth weight status. (Mean, 95% C.I.) 
 
Maternal Plasma Cord Plasma  
LBW 
N=8 
Not LBW 
N=56 
 
p 
LBW 
N=8 
Not LBW 
N=56 
 
p 
ANTH* 
(pmol/mL) 
4.9 
(0, 14.4) 
7.3 
(4.3, 10.3)
0.585 11.2 
(0, 29.3) 
8.4 
(5.4, 11.3) 
0.725 
BP** 
(pmol/mL) 
3.5 
(2.0, 4.9) 
5.2 
(3.2, 7.1) 
0.139 3.5 
(0.8, 6.2)
3.6 
(2.7, 4.5) 
0.951 
1-HP#
(pmol/mL) 
238.8 
(109.3, 
368.4) 
279.3 
(235.0, 
323.6) 
0.510 269.4 
(144.1, 
394.6) 
280.4 
(240.5, 
320.3) 
0.850 
Cotinine 
(ng/mL) 
47.7 
(28.4, 67.1) 
47.5 
(43.1, 
51.9) 
0.975 60.6 
(33.6, 
87.5) 
44.1 
(37.2, 
51.0)  
0.202 
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 The mean concentration of anthracene in term cord plasma was 
significantly higher than in maternal plasma (Table 7). There was no significant 
difference in concentrations of anthracene in plasma from mothers and infants 
that delivered preterm.  Concentrations of cotinine, benzo(a)pyrene and 1-
hydroxypyrene were similar in maternal and cord plasma, regardless of the 
length of pregnancy.  
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Table 7.   
Concentrations of anthracene,* benzo(a)pyrene,** 1-hydroxypyrene# and 
cotinine in maternal and cord blood plasma by term or preterm delivery.  
(Mean, 95% C.I.) 
 
Term 
N=46 
Preterm 
N=18 
 
Maternal Cord p Maternal Cord p 
ANTH* 
(pmol/mL) 
7.8 
(4.2, 11.5) 
9.4 
(5.5, 13.3)
0.029 4.8 
(1.0, 8.5) 
6.9 
(1.2, 
12.7) 
0.975
BP** 
(pmol/mL) 
5.5 
(3.2, 7.8) 
3.9 
(2.8, 5.1) 
0.372 3.5 
(3.2, 7.8) 
2.7 
(2.8, 
5.1) 
0.486
1-HP#
(pmol/mL) 
285.3 
(232.3, 
338.3) 
272.4 
(239.9, 
304.8) 
0.981 246.1  
(188.1, 
304.1) 
296.0 
(185.8, 
406.1) 
0.938
Cotinine  
(ng/mL) 
47.7 
(43.0, 52.4) 
44.1 
(36.3, 
51.9) 
0.675 46.9 
(36.6, 
57.3) 
51.3 
(37.4, 
65.3) 
0.393
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 When comparing women who delivered preterm and those delivering at 
term (Table 8), all maternal plasma PAH values from women that delivered PT 
trended to be lower than those from women that delivered at term, but there were 
no significant differences.  The mean cord plasma concentration of 
benzo(a)pyrene from infants who delivered prior to 38 weeks was significantly 
lower than that from infants delivered at term.     
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Table 8.   
Concentrations of anthracene,* benzo(a)pyrene,** 1-hydroxypyrene# and 
cotinine by term or preterm delivery. (Mean, 95% C.I.) 
 
Maternal Cord  
Term Preterm p Term Preterm p 
ANTH* 
(pmol/mL) 
7.8 
(4.2, 11.5) 
4.8 
(1.0, 8.5) 
0.232 9.4 
(5.5, 13.3)
6.9 
(1.2, 12.7) 
0.461 
BP** 
(pmol/mL) 
5.5 
(3.2, 7.8) 
3.5 
(2.5, 4.6) 
0.120 3.9 
(2.8, 5.1) 
2.7 
(2.2, 3.2) 
0.046 
1-HP#
(pmol/mL) 
285.3 
(232.3, 
338.3) 
 
246.1 
(188.1, 
304.1) 
 
0.309 272.4 
(239.9, 
304.8) 
296.0 
(185.8, 
406.1) 
 
0.670 
Cotinine 
(ng/mL) 
47.7 
(43.0, 52.4) 
46.9 
(36.6, 
57.3) 
0.888 44.1 
(36.3, 
51.9) 
51.3 
(37.4, 
65.3) 
0.355 
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  Visual inspection of the PAH and cotinine data suggested severe 
skewness, with several extreme values, so a logarithmic transformation was 
applied to each analyte.  Figures 7-10 are scatter plots showing the least squares 
regression of the log transformed concentrations of cord plasma PAH and 
cotinine on the corresponding maternal analytes.  LN anthracene: maternal vs. 
cord plasma shows a significant positive trend of increasing cord concentrations.  
LN benzo(a)pyrene: maternal vs. cord plasma shows a downward trend but the 
linear regression is not statistically significant. The graphical representation of LN 
1-hydroxypyrene: maternal vs. cord shows a slight downward trend but with 
several extreme observations and the regression line for LN cotinine: maternal 
vs. cord shows a slight positive trend but, again, there is a wide distribution of 
values.  Neither of the latter two linear regressions are statistically significant.   
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 Figure 7.   
Scatter plot with linear regression of LN anthracene: maternal vs. cord 
plasma 
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Figure 8.   
Scatter plot with linear regression of LN benzo(a)pyrene: maternal vs. cord 
plasma  
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Figure 9. 
Scatter plot with linear regression of LN 1-hydroxypyrene: maternal vs. 
cord plasma  
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Figure 10. 
Scatter plot with linear regression of LN cotinine: maternal vs. cord plasma  
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 Given the lack of linear association between log-transformed maternal and 
cord plasma concentrations and the presence of so many extreme values, 
Spearman correlations were used to measure the associations between maternal 
and cord plasma concentrations.  There were no significant correlations between 
LN benzo(a)pyrene: cord and any maternal PAH or cotinine, or between LN 
cotinine: cord and any  maternal analyte.  None of the data are shown.  Tables 9-
10 list the remaining Spearman correlations.  Anthracene: cord was significantly 
correlated with anthracene: maternal and cotinine: maternal (Table 9).  1-
hydroxypyrene: cord  was significantly correlated with 1-hydroxypyrene: maternal 
(Table 10).   
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Table 9.   
Spearman correlations between maternal concentrations of anthracene, 
benzo(a)pyrene, 1-hydroxypyrene,  cotinine and cord plasma anthracene. 
 
 Cord Plasma Anthracene 
(pmol/mL) 
Maternal rs p 
Anthracene 
(pmol/mL) 
0.38 0.002 
Benzo(a)pyrene 
(pmol/mL) 
-0.09 0.507 
1-Hydroxypyrene 
(pmol/mL) 
0.13 0.302 
Cotinine 
(ng/mL) 
0.40 0.001 
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Table 10.   
Spearman correlations between maternal concentrations of anthracene, 
benzo(a)pyrene, 1-hydroxypyrene and cotinine and cord plasma 1-
hydroxypyrene. 
 Cord Plasma 1-hydroxypyrene 
(pmol/mL) 
Maternal rs p 
Anthracene 
(pmol/mL) 
0.01 0.965 
Benzo(a)pyrene 
(pmol/mL) 
0.11 0.399 
1-Hydroxypyrene 
(pmol/mL) 
0.25 0.043 
Cotinine 
(ng/mL) 
-0.13 0.323 
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Plasma cotinine concentrations were individually subjected to Spearman 
correlation analysis with each PAH compound separately for the maternal and 
cord concentrations.  In maternal plasma, cotinine was positively correlated with 
1-hydroxypyrene (Table 11).  In cord plasma, cotinine was negatively correlated 
with 1-hydroxypyrene as seen in Table 12.  
Table 11.   
Correlations between maternal plasma concentrations of cotinine and 
individual PAH   
 
MATERNAL COTININE 
 rs p 
Anthracene   
(pmol/mL) 
0.09 0.487 
Benzo(a)pyrene 
(pmol/mL) 
-0.05 0.690 
1-Hydroxypyrene 
(pmol/mL)     
0.30 0.016 
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Table 12. 
Correlations between cord plasma concentrations of cotinine and 
individual PAH 
 
CORD COTININE 
 rS p 
Anthracene 
(pmol/mL) 
0.01 0.912 
Benzo(a)pyrene 
(pmol/mL) 
-0.01 0.915 
1-Hydroxypyrene 
(pmol/mL) 
-0.26 0.038 
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  Maternal plasma PAH compounds correlated significantly with each other 
(Table 13).  However there was no correlation between maternal cotinine and the 
individual PAH (data not shown). 
Table 13.   
Correlations among maternal plasma PAH and cotinine 
MATERNAL  
Benzo(a)pyrene 1-Hydroxypyrene 
 rS p rS P 
Anthracene 
(pmol/mL)    
0.32 0.011 0.32 0.009 
Benzo(a)pyrene 
(pmol/mL)          
  0.28 0.025 
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Unlike what was seen in the maternal plasma, cord plasma PAH 
compounds did not show significant correlations.  However, cotinine: cord did 
correlate significantly with 1-hydroxypyrene. (Table 14). 
Table 14.   
Correlations among cord plasma PAH and cotinine. 
CORD  
Benzo(a)pyrene 1-Hydroxypyrene Cotinine 
 rS p rS p rS p 
Anthracene 
(pmol/mL) 
0.08 0.518 0.03 0.814 0.14 0.912 
Benzo(a)pyrene 
(pmol/mL) 
  0.23 0.065 -0.01 0.915 
1-Hydroxypyrene 
(pmol/mL)     
    -0.26 0.038 
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 After reviewing studies from Jauniaux (178) Ziegler (179)  and Perera (3), 
a maternal cotinine concentration of 35 ng/mL was chosen as a cut-point to 
distinguish between two groups of women:  those whose tobacco smoke 
exposure was limited (none-light) and those whose smoke exposure was more 
significant (moderate-heavy). Differences in maternal PAH concentrations within 
those sub-groups are shown in Table 15.  The concentration of anthracene in the 
moderate-heavy group was more than twice that of the none-light group and was 
statistically significant; the other PAH were not.   
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Table 15.   
Maternal anthracene, benzo(a)pyrene and 1-hydroxypyrene by maternal 
cotinine subgoups (Mean, 95% C.I.) 
 
 Maternal cotinine  
<35 ng/mL 
N=8 
Maternal cotinine  
≥35 ng/mL 
N=56 
 
p 
Anthracene 
(pmol/mL) 
3.0  
(0.6, 5.4) 
7.6  
(4.4, 10.7) 
0.019 
Benzo(a)pyrene 
(pmol/mL) 
3.3  
(1.9, 4.7) 
5.2  
(3.3, 7.1) 
0.105 
1-Hydroxypyrene 
(pmol/mL) 
232.7  
(154.0, 311.4) 
280.2 
(234.4, 326.0) 
0.259 
 
 
When birth weight, gestational age and cord plasma concentrations of 
PAH and cotinine were compared in the two maternal smoking groups, mean 
anthracene remained significantly higher in the moderate-heavy smoking group 
(Table 16).  Cord plasma benzo(a)pyrene was lower in the none-light group, but 
did not reach statistical significance.  There was no statistically significant 
difference in concentrations of 1-hydroxypyrene between the groups. 
Interestingly, cord plasma cotinine was similar between the groups (43.0±24.7 
vs. 46.6±27.3  ng/mL, none-light compared to moderate-heavy, respectively) 
despite an almost 2-fold difference in the maternal cotinine concentrations 
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(27.2±7.7 vs. 50.5±16.2 ng/mL, none-light compared to moderate-heavy, 
respectively).  
Table 16.   
Birth weight, gestational age, cord plasma PAH and cotinine by maternal 
cotinine subgroups (mean, 95% C.I.) 
 
 Maternal cotinine  
<35 ng/mL 
N=8 
Maternal cotinine  
≥35 ng/mL 
N=56 
 
p 
BW (kg) 2.94  
(2.4, 3.5) 
3.09  
(2.9, 3.3) 
0.533 
GA (wks) 36.9  
(35.0, 38.8) 
38.3  
(37.7, 38.8) 
0.151 
ANTH* 
(pmol/mL) 
4.2  
(1.0, 7.4) 
9.4  
(5.8, 12.9) 
0.026 
BP** 
(pmol/mL) 
2.7  
(2.3, 3.2) 
3.7  
(2.8, 4.7) 
0.061 
1-HP#
(pmol/mL) 
262.9 
(156.8, 369.0) 
281.3 
(240.7, 321.9) 
0.717 
Cotinine 
(ng/mL) 
43.0  
(22.3, 63.7) 
46.6  
(39.3, 53.9) 
0.713 
 
*Anthracene 
**Benzo(a)pyrene 
#1-Hydroxypyrene 
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 To summarize the results of this study, there were significant correlations 
between: 
• Maternal and cord concentrations of anthracene,  
• Maternal and cord concentrations of 1-hydroxypyrene,   
• Anthracene, benzo(a)pyrene and 1-hydroxypyrene in maternal plasma,  
• Maternal cotinine and cord anthracene, 
• Maternal cotinine and cord 1-hydroxypyrene,   
• Cord cotinine and cord 1-hydroxypyrene.    
 
There were significant differences between: 
• Cord concentrations of benzo(a)pyrene in term vs. preterm 
• Cord concentrations of anthracene in subgroups based on maternal 
cotinine above or below 35 ng/mL 
• Cord concentrations of anthracene in subgroups of maternal low, 
moderate and heavy smoking prior to delivery 
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DISCUSSION 
 Smoking during pregnancy remains a significant public health concern 
despite considerable evidence of the dangers in scientific literature and lay press. 
The physical evidence for maternal harm from smoking during pregnancy has 
been known for decades and has been discussed earlier in this paper:  
• Miscarriage/spontaneous abortion 
• Placenta previa, placental abruption 
• Preterm delivery 
Infant effects, both immediate and in the months after birth, are also well known 
and have been discussed: 
• Low birth weight (even after a full term gestation) 
• Nicotine withdrawal during the first hours after birth 
• Decreased arousability from sleep  
• Increased risk for sudden infant death syndrome (SIDS) 
The data related to learning delays and behavioral disturbances are less clear 
because of the confounding effects of social and genetic factors.  However, 
concerns remain because of data from animal studies that show the disruptive 
effects of nicotine on neural development.
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 This study began with 4 research questions.   
1. Are anthracene, benzo(a)pyrene and 1-hydroxypyrene present in 
measurable concentrations in maternal and cord blood plasma? 
Yes.  Each PAH was measured in both maternal and cord blood plasma, 
although in some individuals, the concentrations were very low. 
2.  Do plasma concentrations of anthracene, benzo(a)pyrene and/or 1-
hydroxypyrene correlate with cotinine among smoking and non-smoking 
women? 
Maternal cotinine was correlated only with 1-hydroxypyrene in maternal plasma.  
Maternal cotinine did, however, correlate significantly with cord anthracene and 
1-hydroxypyrene.  Within cord plasma samples, as was seen in maternal plasma, 
cotinine was correlated only with 1-hydroxypyrene.     
3.  Do plasma concentrations of anthracene, benzo(a)pyrene and 1-
hydroxypyrene in cord blood parallel levels in maternal plasma? 
Again, the answer is no.  Extremes of concentrations existed within paired 
maternal and cord plasma samples in which very high concentrations in maternal 
plasma were coupled with low concentrations in cord plasma and vice versa.  
Mean anthracene concentrations always trended to be higher in cord plasma 
than in maternal plasma regardless of the subgroup being studied (term, preterm, 
low birth weight), but without reaching statistical significance.  This suggests that 
there may either be a concentrating effect on the fetal side, as has been 
observed with nicotine (138), or that the fetus lacks the enzyme machinery to 
metabolize anthracene to other compounds, perhaps leading to an accumulation 
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over time.   The effect of labor, especially its duration, on the processes involved 
in PAH and cotinine metabolism are not known.  
 Benzo(a)pyrene trended to be higher in maternal plasma than in cord 
while 1-hydroxypyrene was not consistently higher or lower in one or the other 
even though it did correlate with maternal and cord cotinine. 
4.  Are plasma concentrations of anthracene, benzo(a)pyrene and 1-
hydroxypyrene correlated with birth weight or gestational age? 
Although our sample had more low birth weight and preterm infants than would 
be expected, it did not appear that concentrations of any of the measured PAH or 
cotinine were correlated with those outcomes.  This study has shown, however, 
that anthracene, benzo(a)pyrene and 1-hydroxypyrene are present in cord blood 
in measurable concentrations.  
 Given the thousands of chemicals found in tobacco smoke, it is difficult to 
attribute any one effect to a single chemical or group of chemicals.  Much 
research has focused on nicotine and carbon monoxide and the resulting hypoxia 
and vasoconstriction that are believed to be responsible for intrauterine growth 
restriction and low birth weight (95, 122, 139, 180, 181).  Other recent studies 
have linked components of tobacco smoke, especially PAH, to a variety of 
enzymatic, inflammatory and cellular changes in the placenta and the fetus. (43, 
182-190) 
 Unlike a singular event that may or may not coincide with a critical epoch, 
maternal smoking during pregnancy represents chronic exposure of the fetus to 
the thousands of compounds in tobacco smoke many times a day over multiple 
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days or weeks.  Repeated exposure across numerous critical windows may 
amplify the resulting effect from very early in gestation.  Although it is impossible 
to know how many fetal organs, cells, organelles and genes are altered each 
time a woman smokes a cigarette, it clear that these compounds are reaching 
the fetus in measurable quantities.  
 Kentuckians are caught in a vortex of poor health: excessive and 
increasing numbers of low birth weight and preterm infants, rising numbers of 
overweight/obese children and adults with many dying from heart-related 
disease.  A large proportion of these problems can be attributed to the “Kentucky 
3-point lifestyle:” 
• Cigarettes 
• Junk food 
• Inactivity  
If programming theory is correct, we face an even more difficult task to break out 
of that cycle given the numbers of infants that experience sub-optimal gestational 
conditions which are then reinforced by the Kentucky life style.  The 
unacceptably high numbers of infants that experience the ill effects of their 
mothers’ smoking before and after birth are but one facet of the two-pronged 
public health challenge before us:  1) to convince children and adolescents to 
avoid smoking at all and 2) to encourage and support smokers in their efforts to 
quit. This second task is especially important for women who are or who are 
thinking about becoming pregnant. 
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LIMITATIONS OF THE STUDY 
 There were several limitations in this study.   
1. This was a pilot study, and as such, was designed to gather 
preliminary data for a larger study rather than to test a specific 
hypothesis.  There are over 4,000 chemicals in tobacco smoke; this 
study only attempted to study 3.  There are many more that remain 
unstudied. 
2. Maternal blood specimens were drawn at the time of admission to the 
labor and delivery service in order to avoid an extra blood draw for the 
mother.  Thus, there was a time lapse between the maternal specimen 
and the cord blood specimen drawn at delivery.  While cotinine has a 
half-life of 18-20 hours, the time difference between specimens is a 
variable that was not quantified.      
 The prevalence of high concentrations of cotinine suggest there 
were over 85% moderate to heavy smokers in this convenience 
sample, a condition that is highly unlikely.  While cotinine is a good 
screening method, there are factors that could affect cotinine 
concentrations at the time of the blood draw, including the time lapse 
since the last cigarette, routine smoking patterns of the women, 
plasma volume, the duration and intensity of labor, as well as the level 
of environmental exposures other than personal tobacco smoking that 
could increase cotinine levels.  All of these items are unknowns due to 
the anonymity of the blood samples.  A better marker of true tobacco 
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smoke exposure would be hemoglobin-protein adducts, such as 4-
amino-biphenyl.  (191)  Assays for these adducts were not performed 
for this study but will be included in future extensions of this research.      
3. These were anonymous samples, lacking data as to the mother’s 
smoking history, diet, physical parameters of the pregnancy, etc. This 
decision was based on early experience that women smokers were 
quite reluctant to participate in a study that was focused on effects of 
smoking on the fetus. Ultimately this would lead to a bias toward non-
smokers in the sampled population.    
4. While personal smoking is presumed to be the major source of PAH in 
this sample, there are no data as to PAH exposure resulting from air 
pollution or from the woman’s local environment.  A woman’s home or 
work environment that provided excessive exposure to air-borne 
particulates and/or PAH could have a significant effect on the 
concentrations we saw even if she, herself, was not a smoker.  
 
FUTURE RESEARCH 
 This study suggests several additional investigations.  Prospective studies 
of women, smokers and non-smokers, that follow them in detail throughout their 
pregnancies with periodic blood samples and activity diaries, augmented by 
amniotic fluid studies, if warranted by normal clinical care, and delivery studies 
(maternal and cord) would create a more complete picture of gestational 
exposure and effects in the infant.  These studies could include genotyping for 
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enzyme polymorphisms and biomarkers of exposure (DNA or hemoglobin protein 
adducts) as well as quantitation of a wider panel of PAH.   
 Monitoring of PAH or levels of other compounds in women that decrease 
or actually quit smoking during pregnancy would provide insight into the 
persistence of these compounds once smoking is no longer a factor.  Postnatal 
studies of infants, especially those that experienced growth restriction in-utero, 
should focus on early growth recovery (catch-up) and neurodevelopmental 
progress.  Another approach to combating the in-utero growth restriction could 
involve nutritional intervention to promote growth recovery. 
 The same plasma samples from this study can be further analyzed for 
other PAH and their metabolites as well as hemoglobin adducts.  Further study of 
anthracene and its metabolites/adducts may enhance current investigations.  
 Body composition studies of infants that do and do not experience in-utero 
growth restriction from maternal smoking may be useful in helping to determine 
what facet of body growth is constrained by the action of smoking.  New 
technology makes these studies rapid, non-invasive and reliable. 
 A study that is underway involves quantitating these compounds in the 
milk of women that deliver preterm and correlating the results with growth 
outcomes in the nursery.  Due to the benefits of human milk for human babies, 
breastfeeding will almost always be the preferred method of feeding.  However, it 
is important to understand the level to which these compounds in mother’s milk 
may add to an infant’s in- utero body burden.   
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 These and many other studies will continue as tobacco smoking and air 
pollution are here to stay.  Basic science investigators will continue to use 
improving technology to focus on the why and how tobacco impacts human 
health.  Public health professionals will continue to educate policy makers and 
the general public to the importance of eliminating tobacco smoke from the 
environment for the good of everyone, but especially infants and children. 
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